Titan Biotech Ltd
NSE: BSE: 524717
₹1212.15
(6.53%)
Sat, 14 Feb 2026, 08:48 pm
Market Cap10.02B
PE Ratio36.82
Dividend0.16
Health Technology
Biotechnology
24.5KTitan Biotech Analysis
dividend
- Unable to calculate sustainability of dividends as Titan Biotech has not reported any payouts.
- Unable to evaluate Titan Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Titan Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Titan Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Titan Biotech is profitable, therefore cash runway is not a concern.
- Titan Biotech is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (24.6%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.7x debt.
- Titan Biotech's cash and other short term assets cover its long term commitments.
- Interest payments on debt are well covered by earnings (EBIT is 4.9x coverage).
- The level of debt compared to net worth has increased over the past 5 years (39.8% vs 58.8% today).
- Titan Biotech's level of debt (58.8%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Titan Biotech board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Naresh's remuneration is about average for companies of similar size in India.
- Naresh's compensation has been consistent with company performance over the past year, both up more than 20%.
- The tenure for the Titan Biotech management team is about average.
misc
- Titan Biotech is not covered by any analysts.
- Titan Biotech has significant price volatility in the past 3 months.
past
- Titan Biotech has delivered over 20% year on year earnings growth in the past 5 years.
- Titan Biotech used its assets more efficiently than the IN Chemicals industry average last year based on Return on Assets.
- Titan Biotech has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Titan Biotech's earnings growth has exceeded the IN Chemicals industry average in the past year (27.4% vs 9.1%).
- Titan Biotech's 1-year earnings growth is less than its 5-year average (27.4% vs 27.7%)
- Titan Biotech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Titan Biotech is good value based on earnings compared to the IN Chemicals industry average.
- Titan Biotech is good value based on earnings compared to the India market.
- 524717 outperformed the Chemicals industry which returned 2.2% over the past year.
- 524717 outperformed the Market in India which returned -14.5% over the past year.
- Titan Biotech is overvalued based on assets compared to the IN Chemicals industry average.
- BSE:524717 is down -10.5% underperforming the Chemicals industry which returned 6.9% over the past month.
- BSE:524717 is down -10.5% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800